Published in Hum Vaccin on December 01, 2010
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults | NCT00981175
Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother (2013) 0.93
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses (2013) 0.87
Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis (2012) 0.83
Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother (2017) 0.82
Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother (2013) 0.80
Japanese B Encephalitis: An Overview of the Disease and Use of Chimerivax-JE as a Preventative Vaccine. Infect Dis Ther (2013) 0.80
Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review. Hum Vaccin Immunother (2014) 0.76
A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78
Japanese encephalitis. J Neurol Neurosurg Psychiatry (2000) 2.76
Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine (2005) 1.67
Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2010) 1.62
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine (2002) 1.53
Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine (2000) 1.14
Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine (2004) 1.11
A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine (2008) 0.97
Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs (2009) 0.95
Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec (2005) 0.89
Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area. Vaccine (1992) 0.87
Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96
Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis (2009) 3.30
Evaluation of diagnostic tests: dengue. Nat Rev Microbiol (2010) 2.91
The use of dengue nonstructural protein 1 antigen for the early diagnosis during the febrile stage in patients with dengue infection. Pediatr Infect Dis J (2008) 2.50
Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis (2010) 2.33
A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet (2005) 2.31
Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26
Evaluation of an NS1 antigen detection for diagnosis of acute dengue infection in patients with acute febrile illness. Diagn Microbiol Infect Dis (2008) 2.06
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis (2010) 1.96
Sustained transmission of dengue virus type 1 in the Pacific due to repeated introductions of different Asian strains. Virology (2004) 1.94
Tandem oxidation processes using manganese dioxide: discovery, applications, and current studies. Acc Chem Res (2005) 1.75
Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol (2012) 1.74
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A (2006) 1.72
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg (2002) 1.70
Myanmar dengue outbreak associated with displacement of serotypes 2, 3, and 4 by dengue 1. Emerg Infect Dis (2004) 1.68
A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines. Clin Infect Dis (2012) 1.63
An in-depth analysis of original antigenic sin in dengue virus infection. J Virol (2010) 1.63
Evaluation of dengue nonstructural protein 1 antigen strip for the rapid diagnosis of patients with dengue infection. Diagn Microbiol Infect Dis (2009) 1.61
A structured handoff program for interns. Acad Med (2009) 1.58
Use of serum and blood samples on filter paper to improve the surveillance of Dengue in Pacific Island Countries. J Clin Virol (2012) 1.58
Change in Japanese encephalitis virus distribution, Thailand. Emerg Infect Dis (2008) 1.55
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine (2002) 1.53
Dengue virus type 3, South Pacific Islands, 2013. Emerg Infect Dis (2014) 1.50
Rapid displacement of dengue virus type 1 by type 4, Pacific region, 2007-2009. Emerg Infect Dis (2010) 1.47
Lineage extinction and replacement in dengue type 1 virus populations are due to stochastic events rather than to natural selection. Virology (2005) 1.45
Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine (2004) 1.43
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J (2004) 1.38
Insecticide susceptible/resistance status in Aedes (Stegomyia) aegypti and Aedes (Stegomyia) albopictus (Diptera: Culicidae) in Thailand during 2003-2005. J Econ Entomol (2007) 1.33
Diverse dengue type 2 virus populations contain recombinant and both parental viruses in a single mosquito host. J Virol (2003) 1.29
Suppression of dengue transmission by application of integrated vector control strategies at sero-positive GIS-based foci. Am J Trop Med Hyg (2008) 1.28
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Operational research to inform a sub-national surveillance intervention for malaria elimination in Solomon Islands. Malar J (2012) 1.25
Defective interfering viral particles in acute dengue infections. PLoS One (2011) 1.25
Epidemiological and molecular features of dengue virus type-1 in New Caledonia, South Pacific, 2001-2013. Virol J (2014) 1.23
Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis (2006) 1.22
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother (2009) 1.21
Dengue hemorrhagic fever epidemiology in Thailand: description and forecasting of epidemics. Microbes Infect (2002) 1.19
Seroepidemiological survey among schoolchildren during the 2000-2001 dengue outbreak of Ratchaburi Province, Thailand. Southeast Asian J Trop Med Public Health (2003) 1.19
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine (2005) 1.18
First isolation of Japanese encephalitis from Culex quinquefasciatus in Thailand. Southeast Asian J Trop Med Public Health (2005) 1.17
Serological evidence for the co-circulation of multiple dengue virus serotypes in Singapore. Epidemiol Infect (2005) 1.16
Recent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands. PLoS One (2011) 1.10
The threat of chikungunya in Oceania. Western Pac Surveill Response J (2013) 1.10
Trend of temephos resistance in Aedes (Stegomyia) mosquitoes in Thailand during 2003-2005. Environ Entomol (2007) 1.10
Training and dissemination of cognitive behavior therapy for depression in adults: a preliminary examination of therapist competence and client outcomes. J Consult Clin Psychol (2010) 1.09
Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic fever. Pediatr Infect Dis J (2012) 1.08
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg (2005) 1.06
Chikungunya virus infection of cell lines: analysis of the East, Central and South African lineage. PLoS One (2012) 1.06
Multiple regions in dengue virus capsid protein contribute to nuclear localization during virus infection. J Gen Virol (2008) 1.05
Ongoing outbreak of dengue serotype-3 in Solomon Islands, January to May 2013. Western Pac Surveill Response J (2013) 1.04
Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin (2005) 1.02
Phylodynamic analysis of the emergence and epidemiological impact of transmissible defective dengue viruses. PLoS Pathog (2013) 0.97
A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine (2008) 0.97
Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis (2002) 0.97
Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. Virol J (2014) 0.96
Dengue nonstructural protein 1 antigen in the urine as a rapid and convenient diagnostic test during the febrile stage in patients with dengue infection. Diagn Microbiol Infect Dis (2011) 0.95
The first synthesis of the ABC-ring system of 'upenamide. Org Lett (2007) 0.95
Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine (2008) 0.94
Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg (2006) 0.93
Geographic dynamics of viral encephalitis in Thailand. Microbes Infect (2003) 0.93
Diagnosis of dengue infection using various diagnostic tests in the early stage of illness. Southeast Asian J Trop Med Public Health (2004) 0.93
Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virol J (2014) 0.91
Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine (2011) 0.91
Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine (2010) 0.91
Age-specific prevalence of dengue antibodies in Bangkok infants and children. Pediatr Infect Dis J (2008) 0.91
Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg (2006) 0.90
Effectiveness of a course designed to teach handoffs to medical students. J Hosp Med (2010) 0.90
Robotically assisted ablation produces more rapid and greater signal attenuation than manual ablation. J Cardiovasc Electrophysiol (2009) 0.88
Dengue, Japanese encephalitis and Chikungunya virus antibody prevalence among captive monkey (Macaca nemestrina) colonies of Northern Thailand. Am J Primatol (2013) 0.88
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. Pediatr Infect Dis J (2006) 0.87
Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. J Med Assoc Thai (2011) 0.86
Laboratory predictors of dengue shock syndrome during the febrile stage. Southeast Asian J Trop Med Public Health (2010) 0.86
An outbreak of malaria in a forward battalion on active service in East Timor. Mil Med (2003) 0.86
Elevated Japanese encephalitis virus activity monitored by domestic sentinel piglets in Thailand. Vector Borne Zoonotic Dis (2011) 0.85
A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine (2007) 0.84
The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine (2007) 0.84
Dengue virus infection in late pregnancy and transmission to the infants. Pediatr Infect Dis J (2008) 0.84
Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Pediatr Infect Dis J (2014) 0.84
Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes. Clin Infect Dis (2012) 0.83
Seroprevalence of dengue in American Samoa, 2010. Emerg Infect Dis (2013) 0.81
Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis (2014) 0.81
Tumour necrosis factor gene polymorphism in dengue infection: association with risk of bleeding. Paediatr Int Child Health (2013) 0.81
Silent transmission of virus during a Dengue epidemic, Nakhon Pathom Province, Thailand 2001. Southeast Asian J Trop Med Public Health (2006) 0.81
Dengue hemorrhagic fever: knowledge, attitude and practice in Ang Thong Province, Thailand. Southeast Asian J Trop Med Public Health (2003) 0.81
Molecular evolutionary dynamics of Ross River virus and implications for vaccine efficacy. J Gen Virol (2009) 0.80
Hantaan virus antibody prevalence in rodent populations of several provinces of northeastern Thailand. Trop Med Int Health (2002) 0.80
Maternally transferred neutralising dengue antibodies in Thai infants: a pilot study. Ann Trop Paediatr (2003) 0.80
Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother (2013) 0.80
Identification of a cryptic prokaryotic promoter within the cDNA encoding the 5' end of dengue virus RNA genome. PLoS One (2011) 0.80
Infection-associated hemophagocytic syndrome among patients with dengue shock syndrome and invasive aspergillosis: a case series and review of the literature. Southeast Asian J Trop Med Public Health (2011) 0.79